Down -12.14 percent in 4 Weeks, Heres Why Karyopharm Therapeutics Looks Ripe for a Turnaround
KPTI Stock | USD 0.60 0.02 3.23% |
Under 68% of Karyopharm Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Karyopharm Therapeutics suggests that many traders are alarmed. Karyopharm Therapeutics' investing sentiment shows overall attitude of investors towards Karyopharm Therapeutics.
Karyopharm |
Karyopharm Therapeutics is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read at zacks.com
Karyopharm Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Karyopharm Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Karyopharm Therapeutics Fundamental Analysis
We analyze Karyopharm Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Karyopharm Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Karyopharm Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.
Peers
Karyopharm Therapeutics Related Equities
MREO | Mereo BioPharma | 12.39 | ||||
MRSN | Mersana Therapeutics | 5.88 | ||||
NUVB | Nuvation Bio | 5.62 | ||||
BLUE | Bluebird Bio | 1.70 | ||||
NVCT | Nuvectis Pharma | 1.53 | ||||
REPL | Replimune | 1.30 | ||||
ABOS | Acumen Pharmaceuticals | 1.13 | ||||
KRON | Kronos Bio | 1.04 | ||||
GLUE | Monte Rosa | 1.26 | ||||
ASMB | Assembly Biosciences | 1.34 | ||||
CTMX | CytomX Therapeutics | 1.83 | ||||
GOSS | Gossamer Bio | 2.33 | ||||
PMVP | Pmv Pharmaceuticals | 2.65 | ||||
GBIO | Generation Bio | 2.73 | ||||
AGIO | Agios Pharm | 3.28 | ||||
XFOR | X4 Pharmaceuticals | 4.92 | ||||
RLYB | Rallybio Corp | 5.49 | ||||
LYRA | Lyra Therapeutics | 5.56 | ||||
HOOK | Hookipa Pharma | 6.40 |
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |